Inhibitory effects of belatacept on allospecific regulatory T-cell generation in humans

Transplantation

Volumn 96, Issue 8, 2013, Pages 689-696

  Levitsky, Josh ^a   Miller, Joshua ^a,b   Huang, Xuemei ^a   Chandrasekaran, Dhivya ^a   Chen, Li ^a   Mathew, James M ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Belatacept; FOXP3; Mixed lymphocyte reaction; mTOR inhibition; Regulatory T cells

Indexed keywords

BELATACEPT; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD4 ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; MYCOPHENOLIC ACID; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CELL LABELING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; GRAFT RECIPIENT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FLOW CYTOMETRY; GRAFT REJECTION; HEALTHY VOLUNTEERS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MYCOPHENOLIC ACID; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 84886097044     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31829f1607     Document Type: Article

References (41)

1. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
2. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547.
3. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
4. + T regulatory cell generation. Transplantation 2009; 88: 1303.
5. Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Invest Med 2001; 49: 442.
6. Woltman AM, de Fijter JW, Kamerling SW, et al. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol 2000; 30: 1807.
7. Levitsky J, Gallon L, Miller J, et al. Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction. Transplantation 2011; 91: 199.
8. Levitsky J, Miller J, Wang E, et al. Immunoregulatory profiles in liver transplant recipients on different immunosuppressive agents. Hum Immunol 2009; 70: 146.
9. Levitsky J, Mathew JM, Abecassis M, et al. Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology 2013; 57: 239.
10. Seveno C, Coulon F, Haspot F, et al. Induction of regulatory cells and control of cellular but not vascular rejection by costimulation blockade in hamster-to-rat heart xenotransplantation. Xenotransplantation 2007; 14: 25.
11. + T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol 2006; 177: 5868.
12. Pilat N, Wekerle T. Belatacept and Tregs: friends or foes? Immunotherapy 2012; 4: 351.
13. Furuzawa-Carballeda J, Lima G, Uribe-Uribe N, et al. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant Proc 2010; 42: 3489.
14. + regulatory T cell population. J Autoimmun 2010; 34: 111.
15. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086.
16. Davies JK, Barbon CM, Voskertchian A, et al. Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplant 2012; 21: 2047.
17. Riella LV, Liu T, Yang J, et al. Deleterious effect of CTLA4-Ig on a Tregdependent transplant model. Am J Transplant 2012; 12: 846.
18. Chavez H, Beaudreuil S, Abbed K, et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007; 17: 243.
19. Charbonnier LM, Vokaer B, Lemaitre PH, et al. CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells. Am J Transplant 2012; 12: 2313.
20. + regulatory T cells. J Immunol 2003; 171: 3348.
21. Lio CW, Dodson LF, Deppong CM, et al. CD28 facilitates the generation of Foxp3(-) cytokine responsive regulatory T cell precursors. J Immunol 2010; 184: 6007.
22. Barnes MJ, Griseri T, Johnson AM, et al. CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria. Mucosal Immunol 2012.
23. + regulatory T cells. J Biol Chem 2012; 287: 11098.
24. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342.
25. Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11: 1599.
26. Klintmalm GB, Feng S, Lake J, et al. Belatacept-based immunosupression in de novo liver transplant recipients: 1-year experience from a phase II study. Am J Transplant 2011; 11: 137.
27. Levitsky J, Leventhal JR, Miller J, et al. Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Hum Immunol 2012; 73: 141.
28. Macedo C, Walters JT, Orkis EA, et al. Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation 2012; 93: 813.
29. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigenspecific transplantation tolerance. Diabetes 2006; 55: 40.
30. + regulatory T cells. Blood 2005; 105: 4743.
31. Nikolaeva N, Bemelman FJ, Yong SL, et al. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006; 81: 445.
32. Dodge IL, Demirci G, Strom TB, et al. Rapamycin induces transforming growth factor-beta production by lymphocytes. Transplantation 2000; 70: 1104.
33. Fischer R, Turnquist HR, Taner T, et al. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol 2009: 215.
34. + T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018.
35. + T cells. J Immunol 2006; 177: 944.
36. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005; 80: 110.
37. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7: 1722.
38. Fourtounas C, Dousdampanis P, Sakellaraki P, et al. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients. Am J Nephrol 2010; 32: 1.
39. Abadja F, Videcoq C, Alamartine E, et al. Differential effect of cyclosporine and mycophenolic acid on the human regulatory T cells and TH-17 cells balance. Transplant Proc 2009; 41: 3367.
40. + regulatory T cells. Transplantation 2009; 87: 1062.
41. Nulojix, Bristol-Myers Squibb. http://packageinserts.bms.com/pi/pi- nulojix.pdf.